Overview

Evaluation Study of New Compounds With Potential Use in Schizophrenia

Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Different compounds that might modify the glucose regulation in the central nervous system will be evaluated in healthy volunteers. Several examinations will be performed in order to get a detailed plan how these substances might work.
Phase:
Phase 1
Details
Lead Sponsor:
Central Institute of Mental Health, Mannheim
Collaborator:
Max-Planck Institute for Metabolism Research
Treatments:
Cannabidiol
Insulin
Insulin, Globin Zinc